Abstract
Beclomethasone dipropionate (BDP, Clenil UDV) is a well-studied inhaled corticosteroid for the treatment of patients with bronchial asthma (BA). Randomized controlled trials have shown that nebulized therapy with BDP was similar in its efficacy and safety to inhalation therapy with budesonide or fluticasone. Preferred patients for the treatment with nebulized BDP are elderly patients with asthma, unable to correctly perform inhalation with portable devices, patients with steroid-dependent asthma, and patients with a temporary loss of asthma control.
Reference53 articles.
1. Global Initiative for Asthma. Global strategy for asthma management and prevention. Available from www.ginasthma.org. Date last updated. 2012.
2. Bateman E.D., Hurd S.S., Barnes P.J. et al. Global strategy for asthma management and prevention: GINA executive summary. Eur. Respir. J. 2008, v. 31, p. 143-178.
3. Masoli M., Fabian D., Holt S., Beasley R. The global burden of asthma: executive summary of the GINA Dissemination Committee report. Allergy. 2004, v. 59, p. 469-478.
4. Weiss K.B., Sullivan S.D., Lyttle C.S. Trends in the cost of illness for asthma in the United States, 1985—1994. J. Allergy Clin. Immunol. 2000, v. 106, p. 493-499.
5. Asthma insight and management. 2009. Available at: http:// www.takingaimatasthma. com/survey-results.html. Accessed March 9, 2010.